secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004143
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios unveils 2023-2026 catalysts: PYRUKYND approvals, pipeline expansion, cash-flow positivity by 2026
--------------------------------------------------------------------------------

- Five ongoing pivotal PYRUKYND trials in thalassemia, sickle cell, and pediatric PK deficiency.
- Potential FDA approvals: thalassemia 2025, sickle cell 2026, pediatric PK deficiency 2026.
- Expects to complete ENERGIZE/ENERGIZE-T enrollment by mid-2023; RISE UP Phase 2 data and go/no-go by mid-year.
- AG-946 Phase 2a enrollment in LR-MDS completed by year-end 2023; IND filing for PAH stabilizer in PKU planned.
- Appointed Tsveta Milanova as CCO; EU/Great Britain approval for PYRUKYND in adult PK deficiency already received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312523004143/0001193125-23-004143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312523004143/d408672d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer